Good about the pathway AA discussions including for the sickest adults. Randomised double blind trials when the death rate is so high and comparatively survival rates after treatment with remestemcel-L so great, would be unethical.
Good that the FDA is apparently seeing this even if the erstwhile downramper correspondents, cannot.
2024 Here we go again., page-163
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.11 |
Change
-0.005(0.45%) |
Mkt cap ! $1.261B | |||
| Open | High | Low | Value | Volume |
| $1.11 | $1.15 | $1.11 | $5.667M | 5.064M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 94111 | $1.11 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.12 | 70945 | 3 |
View Market Depth
| Last trade - 16.10pm 03/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.12 |
Change
-0.005 ( 1.73 %) |
||||
| Open | High | Low | Volume | ||
| $1.11 | $1.15 | $1.11 | 871975 | ||
| Last updated 15.59pm 03/06/2024 ? | |||||
| MSB (ASX) Chart |